Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for efanesoctocog alfa

  1. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)

    Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.

    Technology appraisal guidance
    Published
    2 April 2025
    View recommendations

    Sections for TA1051

  2. New drug approved for inherited clotting disorder, offering simpler dosing and enhanced quality of life.

    NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.

    News
    Last updated
    28 February 2025